Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.645 USD | -3.72% | +2.67% | -22.95% |
Apr. 18 | Recursion Pharmaceuticals Insider Sold Shares Worth $367,007, According to a Recent SEC Filing | MT |
Apr. 16 | Recursion Pharmaceuticals Names Najat Khan Chief R&D Officer | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.95% | 1.89B | |
-2.20% | 104B | |
+1.56% | 97.42B | |
+0.79% | 22.2B | |
-17.90% | 21.23B | |
-11.11% | 18.33B | |
-42.83% | 16.35B | |
-15.74% | 15.06B | |
+3.97% | 13.98B | |
+34.92% | 11.66B |
- Stock Market
- Equities
- RXRX Stock
- News Recursion Pharmaceuticals, Inc.
- KeyBanc Starts Recursion Pharmaceuticals at Overweight With $20 Price Target